SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 segment
Segment reporting
Number of segments | segment			2		1
Revenue recognition	$ 73,855	$ 48,625	$ 138,332	$ 103,146
Depreciation and amortization	13,764	11,324	28,321	22,222
Selling, general, and administrative	31,958	18,820	60,775	36,407
Operating Loss	(12,913)	(15,553)	(32,108)	(12,508)
Interest expense, net	(6,669)	(2,531)	(13,282)	(4,985)
Other expense, net	764	(67)	675	(582)
Loss Before Benefit for Income Taxes	(18,818)	(18,151)	(44,715)	(18,075)
Operating segments | Generics, Established Brands and Other
Segment reporting
Revenue recognition	63,653	48,625	126,838	103,146
EBITDA	15,473	14,660	30,004	36,499
Operating segments | Rare Disease
Segment reporting
Revenue recognition	10,202		11,494
EBITDA	(6,663)	(4,473)	(17,111)	(5,751)
Unallocated expenses
Segment reporting
Depreciation and amortization	(13,764)	(11,324)	(28,321)	(22,222)
Selling, general, and administrative	(7,959)	(14,416)	(16,680)	(21,034)
Operating Loss	(12,913)	(15,553)	(32,108)	(12,508)
Interest expense, net	(6,669)	(2,531)	(13,282)	(4,985)
Other expense, net	$ 764	$ (67)	$ 675	$ (582)